Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

Por Chan, Jennifer A., Mayer, Robert J., Jackson, Nadine, Malinowski, Paige, Regan, Eileen, Kulke, Matthew H.
Publicado em 2013

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors

Por Chan, Jennifer A., Zhu, Andrew X., Stuart, Keith, Bhargava, Pankaj, Earle, Craig C., Clark, Jeffrey W., Casey, Carolyn, Regan, Eileen, Kulke, Matthew H.
Publicado em 2010

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

Por Kulke, Matthew H., Chan, Jennifer A., Meyerhardt, Jeffrey A., Zhu, Andrew X., Abrams, Thomas A., Blaszkowsky, Lawrence S., Regan, Eileen, Sidor, Carolyn, Fuchs, Charles S.
Publicado em 2010

Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors

Por Chan, Jennifer A., Ryan, David P., Zhu, Andrew X., Abrams, Thomas A, Wolpin, Brian M, Malinowski, Paige, Regan, Eileen M, Fuchs, Charles S., Kulke, Matthew H.
Publicado no Endocr Relat Cancer (2012)

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

Por Phan, Alexandria T, Halperin, Daniel M, Chan, Jennifer A, Fogelman, David R, Hess, Kenneth R, Malinowski, Paige, Regan, Eileen, Ng, Chaan S, Yao, James C, Kulke, Matthew H
Publicado no Lancet Oncol (2015)

A Prospective, Phase I/II Study of Everolimus and Temozolomide in Patients with Advanced Pancreatic Neuroendocrine Tumor

Por Chan, Jennifer A., Blaszkowsky, Lawrence, Stuart, Keith, Zhu, Andrew X., Allen, Jill, Wadlow, Raymond, Ryan, David P., Meyerhardt, Jeffrey, Gonzalez, Marielle, Regan, Eileen, Zheng, Hui, Kulke, Matthew H.
Publicado no Cancer (2013)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

Por Meyerhardt, Jeffrey A., Ancukiewicz, Marek, Abrams, Thomas A., Schrag, Deborah, Enzinger, Peter C., Chan, Jennifer A., Kulke, Matthew H., Wolpin, Brian M., Goldstein, Michael, Blaszkowsky, Lawrence, Zhu, Andrew X., Elliott, Meaghan, Regan, Eileen, Jain, Rakesh K., Duda, Dan G.
Publicado em 2012

Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study

Por Zhu, Andrew X., Ancukiewicz, Marek, Supko, Jeffrey G., Sahani, Dushyant V., Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Abrams, Thomas A., McCleary, Nadine Jackson, Bhargava, Pankaj, Muzikansky, Alona, Sheehan, Susan, Regan, Eileen, Vasudev, Eamala, Knowles, Michelle, Fuchs, Charles S., Ryan, David P., Jain, Rakesh K., Duda, Dan G.
Publicado em 2013

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

Por Wolpin, Brian M., Ng, Kimmie, Zhu, Andrew X., Abrams, Thomas, Enzinger, Peter C., McCleary, Nadine J., Schrag, Deborah, Kwak, Eunice L., Allen, Jill N., Bhargava, Pankaj, Chan, Jennifer A., Goessling, Wolfram, Blaszkowsky, Lawrence S., Supko, Jeffrey G., Elliot, Meaghan, Sato, Kaori, Regan, Eileen, Meyerhardt, Jeffrey A., Fuchs, Charles S.
Publicado em 2013